**Name of journal:** ***World Journal of Gastrointestinal Surgery***

**Manuscript NO: 49465**

**Manuscript type: CASE REPORT**

**Doege-Potter syndrome by malignant solitary fibrous tumor of the liver: A case report and review of literature**

Antonella D *et al*. Malignant solitary fibrous tumor

Delvecchio Antonella, Duda Loren, Conticchio Maria, Fiore Felicia, Lafranceschina Stefano, Umberto Riccelli, Cristofano Antonella, Pascazio Bianca, Colagrande Anna, Resta Leonardo, Memeo Riccardo

**Delvecchio Antonella,** **Conticchio Maria, Fiore Felicia, Lafranceschina Stefano, Riccelli Umberto, Memeo Riccardo,** Department of Emergency and Organ Transplantation, General Surgery Unit “M. Rubino”, University of Bari, Bari 70124, Italy

**Duda Loren, Colagrande Anna, Resta Leonardo,** Department of Pathology, University of Bari, Bari 70124, Italy

**Cristofano Antonella,** Department of Oncology, Ente Ecclesiastico Ospedale F. Miulli, Acquaviva delle Fonti 70021, Italy

**Pascazio Bianca,** Department of General Surgery, Ospedale San Paolo, Bari 70123, Italy

**ORCID number:** Delvecchio Antonella (0000-0002-7759-4340); Duda Loren (0000-0002-8836-4858); Conticchio Maria (0000-0003-3177-5274); Fiore Felicia (0000-0001-7117-7565); Lafranceschina Stefano (0000-0002-6033-8981); Umberto Riccelli (0000-0002-8385-9739); Cristofano Antonella (0000-0002-0941-2875); Pascazio Bianca (0000-0001-6470-1509); Colagrande Anna (0000-0003-4676-0761); Resta Leonardo (0000-0003-4335-4776); Memeo Riccardo (0000-0002-1668-932X).

**Author contributions:** Delvecchio A and Memeo R designed the report and the review; Conticchio M, Fiore F, Pascazio B and Lafranceschina S collected the patient’s clinical data; Riccel U, native English speaker, responsable of revision english language; Duda L, Colagrande A and Resta L provided relevant figures and described anatomopathological characteristics; Cristofano A designed oncological features. All authors issued final approval for the version to be submitted.

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that no conflict of interest exists.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Delvecchio Antonella, MD, Surgeon,** Department of Emergency and Organ Transplantation, General Surgery Unit “M. Rubino”, University of Bari, 17 Street Mario Pagano, Ceglie Messapica, Bari 70124, Italy. [antodel88@libero.it](mailto:antodel88@libero.it)

**Telephone:** +39-32-08013447

**Received:** June 13, 2019

**Peer-review started:** June 19, 2019

**First decision:** August 2, 2019

**Revised:** August 9, 2019

**Accepted:** August 13, 2019

**Article in press:** August 13, 2019

**Published online:** August 27,2019

**Abstract**

***BACKGROUND***

Solitary fibrous tumor of the liver (SFTL) is a rare occurrence with a low number of cases reported in literature. SFTL is usually benign but, 10%-20% cases are reported to be malignant with a tendency to metastasize. The majority of malignant SFTL cases are associated with a paraneoplastic hypoglycaemia defined as Doege-Potter syndrome. Surgery is the best therapeutic treatment, however, long- life follow-up is recommended.

***CASE SUMMARY***

A 74-year-old man, was admitted to the emergency department after a syncopal episode with detection of hypoglycaemia resistant to medical treatment. The computed tomography revealed a solid mass measuring 15 cm of the left liver. An open left hepatectomy was performed with complete resection of tumor. Histopathological analyses confirmed a malignant SFTL.

***CONCLUSION***

Large series with long-term follow-up have not been published neither have clinical trials been undertaken. Consequently, the methodical long-term follow-up of surgically treated SFTLs is strongly recommended.

**Key words:** Solitary fibrous tumor; Malignant solitary fibrous tumor of the liver; Mesenchymal tumor; Hepatic tumor; Doege-Potter syndrome

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Solitary fibrous tumors (SFTs) are rare mesenchymal tumors first described in 1931 by Klemperer and Rabin. Usually, SFTs are benign, but 10%-20% of them are reported to be malignant with a tendency to metastasize. At present, 22 cases of liver malignant SFTs, including our patient, have been reported in literature. Some cases are associated with a paraneoplastic hypoglycaemia definied as Doege-Potter syndrome. Surgery is the best therapeutic modality and prolongs life, but also improves the clinical characteristics associated with Doege-Potter syndrome if present. Longlife follow-up is recommended.

Delvecchio A, Duda L, Conticchio M, Fiore F, Lafranceschina S, Riccelli U, Cristofano A, Pascazio B, Colagrande A, Resta L, Memeo R. Doege-Potter syndrome by malignant solitary fibrous tumor of the liver: A case report and review of literature. *World J Gastrointest Surg* 2019; 11(8): 348-357 URL: https://www.wjgnet.com/1948-9366/full/v11/i8/348.htm DOI: https://dx.doi.org/10.4240/wjgs.v11.i8.348

**INTRODUCTION**

Solitary fibrous tumors (SFTs) are rare mesenchymal tumors first described in 1931 by Klemperer and Rabin[1]. Originally the are usually found in pleura but they have also been reported in other serous cavities such as pericardium and peritoneum. Such tumours have also been described in other unusual organs such as the liver, orbit, retroperitoneum, maxillary sinus, pancreas, upper respiratory tract, lung, soft tissues, kidneys, thyroid gland, meninges, and prostatic gland[2,3].

SFTs of the liver (SFTLs) are some of the most uncommon SFT, with only approximately 84 reported cases in the English literature[1]. SFTs are usually benign, but 10%-20% cases are reported to be malignant with a tendency to metastasize[2]. Histologically, they are characterized by proliferation of spindle cells, and immunohistochemically are positive for CD34 and BCL2 and bland for CD99[4].

Clinico-radiological features are not specific, therefore the diagnosis can be made only on the basis of histopathological data[2]. Some cases of malignant SFTs are associated with a paraneoplastic hypoglycaemia defined as Doege-Potter syndrome, described in pleural and extrapleural tumors[5].

Surgery is considered the best therapeutic modality, with outcomes dependent on resectability. Resection prolongs life, but also improves the clinical characteristics associated with Doege-Potter syndrome if present[6]. Longlife follow-up is recommended. We reported a new case of malignant SFTL treated at our Institute and reviewed 22 cases of this rare tumor present in English scientific literature.

**CASE PRESENTATION**

***History of present illness***

A 74 years old man, was admitted to the emergency department for syncopal episode, with detection of hypoglycaemia resistant to medical treatment.

***History of past illness***

His past medical history included hypertension, benign prostatic hypertrophy and glaucoma.

***Physical examination upon admission***

Physical examination revealed a morbidly obese (body mass index = 35), painless hepatomegaly without weight loss.

***Laboratory examinations***

Investigations reported a marked hypoglycaemia, with capillary blood glucose measurements ranged from 30 to 70 mg/dL treated with continuous glucose infusion and a rich carbohydrate diet.

Laboratory tests revealed low levels of insulin: 0.3 mcrU/mL (range 5-25 mcrU/mL), low levels of C-peptide: < 0.10 ng/dL (range 0.9-4 ng/dL), low levels of GH: <0.02 ng/dL (range 0.02-1.23 ng/dL), normal level of cortisol: 8.9 mcg/dL (range 3.7-19.4 mcg/dL), normal level of insulin-like growth factor I (IGFI): 84 ng/mL (range 20-300 ng/mL) and normal level of insulin-like growth factor II (IGFII): 575.70 ng/mL (range 373-1000 ng/mL) in the patient’s serum. The IGFII/IGFI ratios was 7:1. Liver functions, viral panel, tumor markers (alpha-fetoprotein, carcinoembryonic antigen and cancer antigen 19-9) were within the normal limits.

***Imaging examinations***

A total body computed tomography (CT) was performed and revealed a solid mass measuring 15 cm of the left liver. The intravenous contrast demonstrate an inhomogeneous enhancement for necrosis within the tumour as well as a thick capsule that enhances during the portal phase (Figure 1). Radiological findings on abdominal magnetic resonance (MR) were similar to ones described for abdominal TC with evidence of a voluminous liver mass measuring 15 cm × 13 cm (Figure 2). There was no evidence of metastatic disease

**FINAL DIAGNOSIS**

Doege-Potter syndrome by malignant solitary fibrous tumor of the liver.

**TREATMENT**

A left hepatectomy was performed with complete resection of tumor and free margin were obtained. Intraoperative ultrasound (IOUS) revealed a left liver tumor mass of 15 cm. There were no sign of contiguous organ invasion or other hepatic lesion. The parenchymal transection was performed with an ultrasonic dissector and bipolar sealers. On frozen section SFT present well circumscribed but unencapsulated border with infiltrative pattern and central necrosis (Figure 3).

**OUTCOME AND FOLLOW-UP**

Immediately after surgery glucose serum levels returned to a physiologic daily profile. The patient was discharged on postoperative day four without complications. Histopathological analyses confirmed a malignant SFTL; microscopically, the tumours tissue showed a proliferation of spindle cells with infiltrative pattern of hepatic parenchyma, immunochemistry show strong positivity for CD34 and BCL2 and bland for CD99 and negative for ActinaML, Desmine, Cd117, CK pool, S100. The mitotic activity index Ki67 was 35% (Figure 4). Adjuvant protocol of chemiotherapy with Epirubicin and Ifosfamide was started. The patient was subjected to a strictly follow-up every 3-4 mo in the first 2-3 years after surgey, twice each year up to the 5th year and then once a year after the 5th year. Five months after surgery there were no signs of local recurrence or distant metastases.

**DISCUSSION**

An English literature search regarding “Solitary fibrous tumor of the liver”, “Malignant solitary fibrous tumor of the liver”, “Mesenchymal tumor”, “Hepatic tumor”, “Doege-Potter syndrome” was conducted using the common search engines and the relevant articles were reviewed and analysed. The reference list of each article was inspected searching for other articles reporting SFTL that were analysed and included in this report.

We selected all cases of malignant SFTL reported in the literature considering a total number of 19 articles and we excluded cases of benign SFTL or extrahepatic localization. At present, 22 cases of malignant SFTL, including including the patient described in this article, have been reported in literature (Table 1). All represent case reports except for one case series with three case series described by Maccio *et al*[7].

Malignant SFTL occurs with almost equal distribution between males (11, 50%) and female (11, 50%). It occurs more in the right lobe (14 cases, 64%) than the left one (6 cases, 27%). There was also two cases (9%) of bilateral localization. The average age of these patients was 61.1 years (range 24-80).

The clinical presentation was non-specific, ranging from weakness, fatigue, anorexia, vomiting, progressive jaundice, disorientation, incoherent speech, malaise abdominal bloating, abdominal discomfort, dyspnoea, abdominal pain, abdominal distension, weight loss. The syndrome of hypoglycaemia was seen in about 23%, five of 22 cases reported. There was no specific laboratory tests or tumor markers for malignant SFTL.

In our review 17 patients (77%) were treated with resection: 9 with unknown tumor margins and 8 with free tumor margins. One patient was treated with failed trans-arterial chemo embolization (TACE) and successful resection with unknown margins. Another case was subjected to TACE followed by resection. Two patient underwent to chemotherapy. One patient was treated with a right portal embolization and successful resection with free tumor margins.

Follow up was not available for 4 cases, no sign of local recurrence or distant metastasis in 7 cases (32%) with an average follow up duration of 17 mo. Local recurrence or distant metastasis were found in 11 patients (50%) with a averge time post-surgery of 27 mo.

SFT first described in the year 1931, is a rare neoplasm commonly located in the pleura and this tumor accounts for less than 2% of all soft tissue tumors[8,9]. SFT is considered a benign tumor with the potential for malignant transformation but the classification of this neoplasm is not yet clear in literature[4,10]. SFT of the liver (SFTL) is particularly rare, therefore the classification as a benign or malignant tumor remains controversial[11]. SFTL was reported for the first time in an article published in 1959 by Nevius and Friedman where three SFT in different localizations were described, one of them was a liver SFT and was clinically presented with hypoglycaemia[12].

England *et al*[13] established the criteria for malignant SFT: Mitotic changes (> 4/10 HPFs), tumor necrosis and hemorrhage, nuclear pleomorphism, and metastasis were the major criteria; large tumor size (> 10 cm) and cellular atypia were the minor criteria.

Wilky *et al*[14] classified the SFT into “benign” with no atypical features and no England’s criteria, “borderline” with 1 or more England’s criteria but final classification as benign, and “malignant.” This report described that “borderline” SFT with any of England’s criteria had been related to high risk of recurrence.

In the 2013 WHO classification of tumors of soft tissue and bone, extrapleural SFT was considered a fibroblastic/myofibroblastic neoplasm with uncertain biological behaviour, rarely metastasizing[15]. In the latest modified WHO classification of soft tissue tumors, SFT was divided into two categories: Solitary fibrous tumor and malignant solitary fibrous tumor[16]. However, according to the updated WHO classification of the digestive-system disorders, SFT is considered a benign tumor with the potential for malignant transformation, the benign or malignant classification of this neoplasm has not yet reached a consensus[4,10].

Chen *et al*[1] reported that 16 of 84 SFTL were malignant, which was similar to the intrapleural SFT recurrence rate of 20%-67% among malignant tumors. Histologically the tumour exhibits a hypercellular spindle-cell proliferation creating storiform arrays with hemangiopericytomatous branching vessels and a moderate to marked atypia. There was parenchymal invasion and no vascular infiltration. High mitotic count (12 per HPF) was observed.

Immunochemistry show strong positivity for CD34 and BCL2 and bland for CD99 and negative for EPAR1 Cytokeratin, CD117, DOG1, ActinaML and Desmine. The mitotic activity index Ki67 was in range from 15% to 20%. SFTL tendencies to be well circumscribed and encapsulated or partially encapsulated, with infiltrative pattern and central necrosis and a growth of > 20 cm in diameter. Malignant SFTL is rare with only 22 cases reported in literature including the present case (Table 1). Literature reported that SFTL usually occurs in female patient over 45 years of age, with no apparent predisposition, in either the right or left sides of the liver[1].

Clinical presentation of these tumors is usually non-specific and the majority of the patients are initially asymptomatic, with an incidental diagnosis, until the tumor attains a large size and presents with symptoms due to mass effect with compression of adjacent organs[2]. Clinical symptoms reported are non-specific, such as weight loss, right upper quadrant pain, fatigue, abdominal distension, gastric plenitude associated to nausea and postprandial vomit depending by tumor size[3]. The clinical presentation of malignant SFTL did not differ notably from the clinical presentation of benign SFTL, have described cases with intractable hypoglycemia[17], unspecific symptoms including abdominal pain and weight loss or muscular and neurological symptoms due to metastatic disease[18,19]. Hypoglycemia (diaphoresis, tremor, anxiety, and lost consciousness) accompanying SFT is the predominant symptom of Doege-Potter syndrome, generally is associated with malignant SFT and was first described in 1930 in a case report by Doege[20-22].

Our patient was conducted at our institution for a left liver mass and severe hypoglycaemia. The physical examination was not specific, in the literature the rare possibility of palpating a solid mass located above the right emmiabdomen and epigastrium is reported. In other cases, the abdominal circumference increases and peripheral edema develops[23]. We asked for an endocrinologist consultation, for the persistent hypoglycaemia, that rejected the insulinoma hypothesis for the low levels of insulin and C-peptide and confirmed that the hypoglycaemia was caused by the presence of insulin-like factors produced by the neoplasm. Although the serum values of IGF-I and IGF-II were normal, the IGFII/IGFI ratios was high.

The IGFII/IGFI ratio is considered a marker of high IGF-II concentration; a ratio of 3: 1 is normal, and in most IGFII-producing tumors the ratio is 10:1. In our case, the spontaneous symptomatic hypoinsulinemic hypoglycaemia, increased IGII/IGFI ratio (7:1), suppression of GH, and the associated clinical features made IGF-II-mediated hypoglycaemia the most likely aetiology.

The typical mechanism involves ectopic tumor production of insulin or other similar hormone such us insulin-like growth factor IGF-II, called “big IGF-II,” which has insulin-like effects on the body, stimulating glucose uptake by insulin-sensitive tissues and the tumor itself[3]. IGF-II expression is high during fetal life and is relatively independent from growth hormone. That is the reason why its expression is coherent with the development of this primitive mesenchymal tumor[3]. It has been observed that the hypoglycemia intractable is associated with malignant transformation, suggesting that this phenomena is due to increased biologic activity in malignant SFTL cells[17]. No specific laboratory parameters findings for SFTL are currently available. Laboratory tests such as blood count or C reactive protein, serum tumor markers such as carcinoembryonic antigen (CEA), alpha-fetal-protein (AFP), and carbohydrate antigen 19-9 (CA19-9) are normal[3,23,24].

Radiological studies are unspecific and cannot be definitively distinguish between malignant or benign hepatic tumors. Ultrasound identifies the presence of a solid well-defined ovoid heterogeneous mass, in some cases homogenous and hyperechoic compared with the normal hepatic parenchyma. Computed tomography with intravenous contrast demonstrate a well-defined encapsulated hypervascular tumor and progressive heterogeneous enhancement, it is possible to identify cystic/necrotic areas within the mass. Radiological findings on abdominal MR are similar to the ones described for abdominal CT. The clinical utility of positron emission tomography (PET) in SFTL has not been established[2,9,25].

The majority of SFTL display benign clinical features, even if it should always be considered potentially malignant. R0 surgical resection remains the only therapeutic option and it has been proved to the solution to normalize glycaemia. In these patients lifelong follow-up is recommended for the high risk of recurrence[3,17,26]. Considering the literature, benefit of radio and chemotherapy is unknown, as well as prognosis due to the little experience and understanding of the biological nature of the disease[27].

**CONCLUSION**

Large series with long-term follow-up have not been published neither clinical trials have been undertaken. For all of these reasons, the methodical long-term follow-up of surgically treated SFTLs is strongly recommended.

**REFERENCES**

1 **Chen N**, Slater K. Solitary fibrous tumour of the liver-report on metastasis and local recurrence of a malignant case and review of literature. *World J Surg Oncol* 2017; **15**: 27 [PMID: 28100235 DOI: 10.1186/s12957-017-1102-y]

2 **Shinde RS**, Gupta A, Goel M, Patkar S. Solitary fibrous tumor of the liver - An unusual entity: A case report and review of literature. *Ann Hepatobiliary Pancreat Surg* 2018; **22**: 156-158 [PMID: 29896577 DOI: 10.14701/ahbps.2018.22.2.156]

3 **Beltrán MA**. Solitary Fibrous Tumor of the Liver: a Review of the Current Knowledge and Report of a New Case. *J Gastrointest Cancer* 2015; **46**: 333-342 [PMID: 26490964 DOI: 10.1007/s12029-015-9769-1]

4 **Feng LH**, Dong H, Zhu YY, Cong WM. An update on primary hepatic solitary fibrous tumor: An examination of the clinical and pathological features of four case studies and a literature review. *Pathol Res Pract* 2015; **211**: 911-917 [PMID: 26601735 DOI: 10.1016/j.prp.2015.09.004]

5 **Du EH**, Walshe TM, Buckley AR. Recurring rare liver tumor presenting with hypoglycemia. *Gastroenterology* 2015; **148**: e11-e13 [PMID: 25529805 DOI: 10.1053/j.gastro.2014.09.036]

6 **Zafar H**, Takimoto CH, Weiss G. Doege-Potter syndrome: hypoglycemia associated with malignant solitary fibrous tumor. *Med Oncol* 2003; **20**: 403-408 [PMID: 14716039 DOI: 10.1385/MO:20:4:403]

7 **Maccio L**, Bonetti LR, Siopis E, Palmiere C. Malignant metastasizing solitary fibrous tumors of the liver: a report of three cases. *Pol J Pathol* 2015; **66**: 72-76 [PMID: 26017883 DOI: 10.5114/pjp.2015.51156]

8 **Dey B**, Gochhait D, Kaushal G, Barwad A, Pottakkat B. Solitary Fibrous Tumor of the Liver: A Rare Tumor in a Rarer Location. *Rare Tumors* 2016; **8**: 6403 [PMID: 27746883 DOI: 10.4081/rt.2016.6403]

9 **Esteves C**, Maia T, Lopes JM, Pimenta M. Malignant Solitary Fibrous Tumor of the Liver: AIRP Best Cases in Radiologic-Pathologic Correlation. *Radiographics* 2017; **37**: 2018-2025 [PMID: 29131777 DOI: 10.1148/rg.2017160200]

10 **Bosman FT**. WHO classification of tumours of the digestive system-NLM Catalog-NCBI. In: WHO classification of tumours of the digestive system. 2010

11 **Yugawa K**, Yoshizumi T, Mano Y, Kurihara T, Yoshiya S, Takeishi K, Itoh S, Harada N, Ikegami T, Soejima Y, Kohashi K, Oda Y, Mori M. Solitary fibrous tumor in the liver: case report and literature review. *Surg Case Rep* 2019; **5**: 68 [PMID: 31020464 DOI: 10.1186/s40792-019-0625-6]

12 **NEVIUS DB**, FRIEDMAN NB. Mesotheliomas and extraovarin thecomas with hypoglycemic and nephrotic syndromes. *Cancer* 1959; **12**: 1263-1269 [PMID: 14426759 DOI: 10.1002/1097-0142(195911/12)12:6<1263::AID-CNCR2820120620>3.0.CO;2-4]

13 **England DM**, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. *Am J Surg Pathol* 1989; **13**: 640-658 [PMID: 2665534 DOI: 10.1097/00000478-198908000-00003]

14 **Wilky BA**, Montgomery EA, Guzzetta AA, Ahuja N, Meyer CF. Extrathoracic location and "borderline" histology are associated with recurrence of solitary fibrous tumors after surgical resection. *Ann Surg Oncol* 2013; **20**: 4080-4089 [PMID: 24046107 DOI: 10.1245/s10434-013-3241-x]

15 **Fisher C**. Atlas of Soft Tissue Tumor Pathology. New York: Springer, 2013

16 **Jo VY**, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. *Pathology* 2014; **46**: 95-104 [PMID: 24378391 DOI: 10.1097/PAT.0000000000000050]

17 **Chan G**, Horton PJ, Thyssen S, Lamarche M, Nahal A, Hill DJ, Marliss EB, Metrakos P. Malignant transformation of a solitary fibrous tumor of the liver and intractable hypoglycemia. *J Hepatobiliary Pancreat Surg* 2007; **14**: 595-599 [PMID: 18040628 DOI: 10.1007/s00534-007-1210-0]

18 **Peng L**, Liu Y, Ai Y, Liu Z, He Y, Liu Q. Skull base metastases from a malignant solitary fibrous tumor of the liver. A case report and literature review. *Diagn Pathol* 2011; **6**: 127 [PMID: 22192457 DOI: 10.1186/1746-1596-6-127]

19 **Yilmaz S**, Kirimlioglu V, Ertas E, Hilmioglu F, Yildirim B, Katz D, Mizrak B. Giant solitary fibrous tumor of the liver with metastasis to the skeletal system successfully treated with trisegmentectomy. *Dig Dis Sci* 2000; **45**: 168-174 [PMID: 10695631 DOI: 10.1023/A:1005438116772]

20 **Chamberlain MH**, Taggart DP. Solitary fibrous tumor associated with hypoglycemia: an example of the Doege-Potter syndrome. *J Thorac Cardiovasc Surg* 2000; **119**: 185-187 [PMID: 10612786 DOI: 10.1016/S0022-5223(00)70242-X]

21 **Heuer GJ**. Intrathoracic tumors: experiences with eight cases of tumor of the thoracic wall pleura and mediastinum. *Ann Surg* 1924; **79**: 670-686 [PMID: 17865026 DOI: 10.1097/00000658-192405000-00003]

22 **Famà F**, Le Bouc Y, Barrande G, Villeneuve A, Berry MG, Pidoto RR, Saint Marc O. Solitary fibrous tumour of the liver with IGF-II-related hypoglycaemia. A case report. *Langenbecks Arch Surg* 2008; **393**: 611-616 [PMID: 18418627 DOI: 10.1007/s00423-008-0329-z]

23 **Ji Y**, Fan J, Xu Y, Zhou J, Zeng HY, Tan YS. Solitary fibrous tumor of the liver. *Hepatobiliary Pancreat Dis Int* 2006; **5**: 151-153 [PMID: 16481304]

24 **Makino Y**, Miyazaki M, Shigekawa M, Ezaki H, Sakamori R, Yakushijin T, Ohkawa K, Kato M, Akasaka T, Shinzaki S, Nishida T, Miyake Y, Hama N, Nagano H, Honma K, Morii E, Wakasa K, Hikita H, Tatsumi T, Iijima H, Hiramatsu N, Tsujii M, Takehara T. Solitary fibrous tumor of the liver from development to resection. *Intern Med* 2015; **54**: 765-770 [PMID: 25832939 DOI: 10.2169/internalmedicine.54.3053]

25 **Soussan M**, Felden A, Cyrta J, Morère JF, Douard R, Wind P. Case 198: solitary fibrous tumor of the liver. *Radiology* 2013; **269**: 304-308 [PMID: 24062563 DOI: 10.1148/radiol.13121315]

26 **Weitz J**, Klimstra DS, Cymes K, Jarnagin WR, D'Angelica M, La Quaglia MP, Fong Y, Brennan MF, Blumgart LH, Dematteo RP. Management of primary liver sarcomas. *Cancer* 2007; **109**: 1391-1396 [PMID: 17315167 DOI: 10.1002/cncr.22530]

27 **Novais P**, Robles-Medranda C, Pannain VL, Barbosa D, Biccas B, Fogaça H. Solitary fibrous liver tumor: is surgical approach the best option? *J Gastrointestin Liver Dis*2010; **19**: 81-84 [PMID: 20361081]

28 **Fuksbrumer MS**, Klimstra D, Panicek DM. Solitary fibrous tumor of the liver: imaging findings. *AJR Am J Roentgenol* 2000; **175**: 1683-1687 [PMID: 11090404 DOI: 10.2214/ajr.175.6.1751683]

29 **Terkivatan T**, Kliffen M, de Wilt JH, van Geel AN, Eggermont AM, Verhoef C. Giant solitary fibrous tumour of the liver. *World J Surg Oncol* 2006; **4**: 81 [PMID: 17118185 DOI: 10.1186/1477-7819-4-81]

30 **Brochard C**, Michalak S, Aubé C, Singeorzan C, Fournier HD, Laccourreye L, Calès P, Boursier J. A not so solitary fibrous tumor of the liver. *Gastroenterol Clin Biol* 2010; **34**: 716-720 [PMID: 20864281 DOI: 10.1016/j.gcb.2010.08.004]

31 **Belga S**, Ferreira S, Lemos MM. A rare tumor of the liver with a sudden presentation. *Gastroenterology* 2012; **143**: e14-e15 [PMID: 22841736 DOI: 10.1053/j.gastro.2012.02.045]

32 **Jakob M**, Schneider M, Hoeller I, Laffer U, Kaderli R. Malignant solitary fibrous tumor involving the liver. *World J Gastroenterol* 2013; **19**: 3354-3357 [PMID: 23745040 DOI: 10.3748/wjg.v19.i21.3354]

33 **Vythianathan M,** Yong J. A rare primary malignant solitary fibrous tumour of the liver. Pathology 2013;[DOI: 10.1097/01.pat.0000426954.68370.26]

34 **Song L**, Zhang W, Zhang Y. (18)F-FDG PET/CT imaging of malignant hepatic solitary fibrous tumor. *Clin Nucl Med* 2014; **39**: 662-664 [PMID: 24686215 DOI: 10.1097/RLU.0000000000000431]

35 **Silvanto A**, Karanjia ND, Bagwan IN. Primary hepatic solitary fibrous tumor with histologically benign and malignant areas. *Hepatobiliary Pancreat Dis Int* 2015; **14**: 665-668 [PMID: 26663016 DOI: 10.1016/S1499-3872(15)60365-4]

36 **De Los Santos-Aguilar RG**, Chávez-Villa M, Contreras AG, García-Herrera JS, Gamboa-Domínguez A, Vargas-Sánchez J, Almeda-Valdes P, Reza-Albarrán AA, Iñiguez-Ariza NM. Successful Multimodal Treatment of an IGF2-Producing Solitary Fibrous Tumor With Acromegaloid Changes and Hypoglycemia. *J Endocr Soc* 2019; **3**: 537-543 [PMID: 30788455 DOI: 10.1210/js.2018-00281]

**P-Reviewer:** de Bree E, Isik A, Rubbini M

**S-Editor:** Ma RY **L-Editor:** A **E-Editor:** Zhou BX

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Italy

**Peer-review report classification**


Grade A (Excellent): A

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0




**Figure 1 Abdominal computed tomography displaying the left liver mass.** A: Arterial phase. B: Portal phase. C: Coronal view.



**Figure 2 Abdominal magnetic resonance imaging displaying the left liver mass.** A: T1. B: T2.



**Figure 3 Macroscopic aspect of solitary fibrous tumor liver.**



**Figure 4 Microscopic findings of solitary fibrous tumor liver.** A: Microscopically, the tumours tissue showed a proliferation of spindle cells with infiltrative pattern of hepatic parenchyma. Immunohistochemically, the tumour cells were strongly positive for CD34 (B) and for BCL2 (C). Weakly positive for CD99 (D).

**Table 1 Solitary fibrous tumor liver cases with malignant features**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **No** | **Author**  **(Year)** | **Age/**  **Sex** | **Presentation** | **Lobe** | **Size** | **Treatment** | **Histopathology** | **Tumor**  **markers** | **IHC** | **Follow up** |
| 1 | Fuksbrumera *et al*[28] (2000) | 71/F | NA | R | 14 × 17 | Resection (UM) | Increased nuclear  atypia, mitoses 8/10  HPF | NA | CD34+,  Bcl2+,  V+ | NA |
| 2 | Yilmaz *et al*[18]  (2000) | 25/F | Weakness,fatigue, anorexia, vomiting and progressive  jaundice | L + R | 32 × 30 | Resection (UM) | Cellularity ranged from  20%-60%, necrosis,  hypervascularity | NAD | V+ | Bone metastasis 1 mo postsurgery managed with  6 mo of chemo (cyclophosphamide, adriamycin) |
| 3 | Terkivatan *et al*[29]  (2006) | 74/M | Gastric fullness, postprandial nausea, and weight loss | L | 24 × 21 × 15 | Resection (FM) | A few highly cellular areas mitoses 10 - 13/10 HPF | NAD | CD34+,  CD99+,  Bcl2+,  V+ | 12 mo no signs of local recurrence or distant metastases |
| 4 | Chan *et al*[16]  (2007) | 70/M | Hypoglycaemia, progressive  jaundice | R | 27 × 24 × 12 | Failed TACE 6 wk  preoperatively  followed by  successful resection  (UM) | Mildly atypical spindle  cells, highly cellular,  plemorphia, necrosis,  mitoses > 20 HPF | CA-125: 145 U/mL  (normal< 35 U/mL) | CD34+,  CD99+,  bcl2+,  V+ | bilateral lung metastasis  and bi-lobar recurrence at 9 mo |
| 5 | Brochard *et al*[30] (2010) | 54/M | Abdominal pain,  weight loss | R | 17 | Resection (FM) | Moderately cellular,  polymorphic cells,  mitoses < 5/10 HPF | NAD | CD34+,  V+,  desmin+, actin+ | Patient died 1 mo after for Local recurrence 6 yr postsurgery, cranial base metastasis, Retroperitoneal and iliac bone metastasis |
| 6 | Fama *et al*[21]  (2008) | 68/M | Hypoglycaemic coma | R | 15 | Resection (FM) | Hypercellular, moderately atypical nuclei, mitoses 20/10 HPF | NAD | CD34+, Bcl2+ | 25 mo no signs of local recurrence or distant metastases |
| 7 | Peng *et al*[17]  (2011) | 24/F | Abdominal discomfort  and distention | R | 30 × 17 × 15 | TACE few days prior  to resection (FM) | Highly cellular,  pleomorphic, necrosis,  mitoses > 10/HPF | CA-125  augmented | CD34+,  bcl2+,  V+ | Patient died 16 mo after initial surgery for skull base metastases, Vertebral metastasis |
| 8 | Belga *et al*[31]  (2012) | 66/F | Increase in  abdominal girth | R | 14 | Resection (UM) | Mitoses > 4/10 HPF,  necrosis, mild nuclear atypia | NAD | CD34+ | 30 mo no signs of local recurrence or distant metastases |
| 9 | Jakob *et al*[32]  (2013) | 62/F | Upper abdominal  pain, weight  loss | L | NA | Resection (UM) | High cellularity,  cytological atypia,  necrosis, mitoses 6/10 HPF | NAD | CD34+,  CD99+,  bcl2+ | NA |
| 10 | Vythianathan  and Yong[33]  (2013) | 78/M | Epigastric pain | L | 17 × 13 | Resection (UM) | Cellular pleomorphism,  necrosis, mitoses > 4/10 HPF | NA | CD34+,  CD99+,  bcl2+,  V+ | NA |
| 11 | Song *et al*[34]  (2014) | 49/M | Abdominal pain | L+R | 7.6 × 5 × 4.8 | Resection (UM) | NAD | NA | CD34+,  bcl2+,  V+ | NA |
| 12 | Du *et al*[4]  (2015) | 55/F | Hypoglycaemia,  weight loss | L | 15.3 × 15.5 × 15.4 | Resection (UM) | NA | NAD | CD34+,  bcl-2+ | Local recurrence 5 yr postsurgery, resected |
| 13 | Feng *et al*[8]  (2015) | 52/F | NA | R | 12 | Resection (UM) | Haemorrhage, necrosis | NAD | CD34+ | Local recurrence 2 yr postsurgery on L lobe managed with PEI. New lesion 6 mo after PEI |
| 14 | Silvanto *et al*[35]  (2015) | 65/M | Incidental finding | L | 18 | Resection (FM) | Myxoid changes, infarction, necrosis mitoses 5-7/10 HPF | NAD | CD34+,  CD99+,  Bcl2+ | 16 mo no signs of local recurrence or distant metastases |
| 15 | Maccio *et al*[26]  (2015) | 74/F | Right abdominal pain,  distension | R | 24 × 16 | Resection (UM) | Nuclear pleomorphism,  cytological atypia,  necrosis, haemorrhage,  mitoses 9/10 HPF | NA | CD34+,  Bcl2+,  V+,  STAT6+ | Lung, omentum, mesentery and abdominal wall metastasis at 9 mo. Patient died 4 mo later |
| 16 | 80/F | Dyspnoea,  cough, asthenia,  abdominal pain | R | 19 × 15 | Palliative  Chemotherapy | Highly cellular,  pleomorphism,  necrosis, haemorrhage,  mitoses 7/10 HPF | NA | CD34+,  Bcl-2+,  V+,  STAT6+ | R lung metastasis.  Patient died 5 mo later |
| 17 | 65/M | Abdominal  discomfort,  vomiting and pain | R | 3 × 2 | Chemotherapy | Cytological atypia, necrosis, mitoses > 6/10 HPF | NA | CD34+,  Bcl2+,  V+,  STAT6+ | Bilateral lung metastasis.  Patient died 5 mo later |
| 18 | Nelson *et al*[1]  (2016) | 61/M | Diarrhoea | R | 15 × 11.5 × 7.5 | Resection (FM) | Myxoid changes,  mitoses > 9/10 HPF | NAD | CD34+,  CD99+,  Bcl2+ | Extensive local recurrence and pleural metastases.  Patient died 6 yr post-surgery |
| 19 | Esteves *et al*[7] (2018) | 68/F | Incidental finding | R | 13.3 × 11.6 × 13.5 | Resection (FM) | Focal high-grade cytologic atypia, mitoses 25-27/10 HPF | NAD | CD34+,  STAT6+ | 20-mo follow-up multiple bilateral pul­monary |
| 20 | De Los Santos-Aguilar *et al*[36]  (2019) | 61/M | hypoglycemia disorientation, incoherent speech | R | 16 × 13 × 11 | Right portal embolization.  Six weeks after resection (FM) | High proliferation  rate of 8/10 HPF  Ki-67 15% | NAD | CD34+, Bcl2+,  CD99+ | No evidence of metastases |
| 21 | Yugawa *et al*[10]  (2019) | 49/F | Malaise abdominal bloating | R | 14 | Resection (FM) | Foci of hemorrhage and necrosis  Mitosis 1/20 HPF) | NAD | STAT6+  V+ | 12 mo no signs of local recurrence or distant metastases |
| 22 | Present case | 74/M | Hypoglycemia | L | 15 × 13 | Resection (FM) | Moderately cellular,  pleomorphism,  necrosis,  mitoses 4/10 HPF  Ki-67 35% |  | CD34+, Bcl2+,  CD99+ | At the moment, 2 mo no signs of local recurrence or distant metastases |

IHC: Immunohistochemistry; M: Male; F: Female; L: Left; R: Right; NA: Not available; UM: Unknown margins; FM: Free margins; HPF: High-power fields; TACE: Transarterial chemoembolization; NAD: No abnormality detected; PEI: Percutaneous ethanol injection; V: Viment.